Condition
Pertussis Vaccines
Total Trials
4
Recruiting
0
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 4 (1)
Trial Status
Active Not Recruiting2
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06903221Phase 4Active Not Recruiting
A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation With Bordetella Pertussis Using Controlled Human Infection
NCT07418372Phase 1Not Yet Recruiting
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
NCT06888076Active Not RecruitingPrimary
Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women
NCT02014519Not ApplicableCompleted
A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary
Showing all 4 trials